Company

Company Drug

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced first patient dosing in a Phase II clinical...

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026

Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...

Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026

Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s...

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Fineline Cube Mar 18, 2026

Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for...

Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Fineline Cube Mar 18, 2026

Shanghai Ark Biopharmaceutical Co., Ltd. has submitted an initial public offering (IPO) filing to the...

Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Fineline Cube Mar 18, 2026

Everest Medicines Limited (HKG: 1952) announced the signing of a letter of intent to acquire...

Company Drug

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

Fineline Cube Mar 18, 2026

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating...

Company Drug

AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer – Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial

Fineline Cube Mar 18, 2026

AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with...

Company Deals

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

Fineline Cube Mar 18, 2026

Kintor Pharmaceutical Limited (HKG: 9939) has entered into a strategic partnership with Shanghai Shangmei Cosmetics...

Company Drug

UniXell Bio Secures FDA Approval for UX‑GIP001 – First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials

Fineline Cube Mar 18, 2026

Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC‑derived allogeneic cell therapy UX‑GIP001 has received...

Company Medical Device

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Fineline Cube Mar 18, 2026

Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis...

Company Drug

Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect – Self‑Pay Pricing for Dual‑Target Obesity Drug

Fineline Cube Mar 18, 2026

Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single‑patient‑use Zepbound...

Company Medical Device

Peijia Medical Secures First FDA 510(k) Clearance for DCwire Micro Guidewire – US Market Entry Milestone

Fineline Cube Mar 18, 2026

Peijia Medical Ltd (HKG: 9996) announced that its DCwire micro guidewire has received 510(k) clearance...

Company Drug

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

Fineline Cube Mar 17, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that subsidiary Shanghai Henlius...

Company Drug

CSPC Pharma Secures Dual NMPA‑FDA Approval for PDE4B Inhaler SYH2059 – First‑in‑Class ILD Candidate Enters Global Clinical Development

Fineline Cube Mar 17, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder...

Company Drug

Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial – First‑in‑Class PD‑L1/VEGFR2 Bispecific ADC Enters Clinic

Fineline Cube Mar 17, 2026

Alphamab Oncology (HKG: 9966) has successfully dosed the first patient in the Phase I clinical...

Company Deals

PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug

Fineline Cube Mar 17, 2026

PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry...

Company Drug Policy / Regulatory

Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates – APG‑115 and HSK42360 Target High‑Unmet‑Need Childhood Cancers

Fineline Cube Mar 17, 2026

China’s Center for Drug Evaluation (CDE) has selected two innovative oncology assets for its Support...

Company Digital

Roche Deploys 2,176 NVIDIA GPUs in Global AI Factory – Largest Pharma GPU Footprint Expands to 3,500+ Blackwell Units

Fineline Cube Mar 17, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) announced the expansion of its global AI infrastructure through the...

Company

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer – Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

UniXell Bio Secures FDA Approval for UX‑GIP001 – First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect – Self‑Pay Pricing for Dual‑Target Obesity Drug

Peijia Medical Secures First FDA 510(k) Clearance for DCwire Micro Guidewire – US Market Entry Milestone

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

CSPC Pharma Secures Dual NMPA‑FDA Approval for PDE4B Inhaler SYH2059 – First‑in‑Class ILD Candidate Enters Global Clinical Development

Alphamab Oncology Doses First Patient in JSKN027 Phase I Trial – First‑in‑Class PD‑L1/VEGFR2 Bispecific ADC Enters Clinic

PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug

Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates – APG‑115 and HSK42360 Target High‑Unmet‑Need Childhood Cancers

Roche Deploys 2,176 NVIDIA GPUs in Global AI Factory – Largest Pharma GPU Footprint Expands to 3,500+ Blackwell Units

You Missed

Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy

3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia

Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer

Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda